VivoSeq
Other

HIE

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

HIE is an early-stage landscape with 0 programs across 3 companies. The most active players are AbbVie, Boryung Pharmaceutical Co., Ltd, CeloNova BioSciences, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

PreclinicalBoryung Pharmaceutical Co., Ltd logo

Boryung Pharmaceutical Co., Ltd

0 programs

PreclinicalC

CeloNova BioSciences, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed8 · 67%
Unknown status1 · 8%
Withdrawn1 · 8%
Active, not recruiting1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Active, not recruiting·—·Phase 3·NCT05413915·164 enrolled
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
Completed·—·Phase 3·NCT02550665·176 enrolled
NVD in Hypothermic HIE Neonates
Completed·MMedical University of South Carolina·Phase 1·NCT04643821·30 enrolled
Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy
Completed·AbbVie logoAbbVie·Phase 4·NCT02121847·40 enrolled
Combined Dental Bleaching Protocols and Time Required to Achieve Satisfactory Color
Completed·AAndré Luis Faria e Silva·Phase 4·NCT03514797·26 enrolled
Evaluation of Symptom-specific Goal Achievement
Completed·SSamsung Medical Center·Phase 4·NCT00836823·130 enrolled
Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis
Completed·QQilu Hospital of Shandong University·N/A·NCT02088216·161 enrolled
Fimasartan Achieving SBP Target (FAST) Study
Completed·Boryung Pharmaceutical Co., Ltd logoBoryung Pharmaceutical Co., Ltd·Phase 4·NCT02495324·369 enrolled
Achieving Normal Glucose In Hospital Settings
Completed·UUniversity of Cambridge·N/A·NCT01359241·16 enrolled
COBRA SHIELD OCT Study
Terminated·CCeloNova BioSciences, Inc.·N/A·NCT02224235·8 enrolled
Preliminary Investigation of ViaShield™ Amnion Patch as an Anti-Adhesive Barrier in Hemicraniectomies
Withdrawn·GGlobus Medical Inc·N/A·NCT03371316
A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT01464281·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)